Validating PRL2 as a New Therapeutic Target in T-ALL
Validating PRL2 as a New Therapeutic Target in T-ALL
Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY
Targeting RNA Condensates in Pediatric Myeloid Leukemia
Targeting RNA Condensates in Pediatric Myeloid Leukemia
Dr. Bruno Di Stefano, Ph.D. – Baylor College of Medicine, Houston, TX
Thyroid Hormone Induces Terminal Differentiation of Tumor Cells in Medulloblastoma
Thyroid Hormone Induces Terminal Differentiation of Tumor Cells in Medulloblastoma
Dr. Zeng-jie Yang – The Research Institute of Fox Chase Cancer Center, Philadelphia, PA
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Dr. Matthew Witkowski – University of Colorado Denver, AMC and DC
Targeting the HMGA1 Chromatin Regulator in MLL1-Rearranged Pediatric Leukemia
Targeting the HMGA1 Chromatin Regulator in MLL1-Rearranged Pediatric Leukemia
Dr. Linda Resar – Johns Hopkins University School of Medicine, Baltimore, MD
Brain Network Organization and Long-Term Cognitive Outcome in Pediatric Brain Tumor Patients
Brain Network Organization and Long-Term Cognitive Outcome in Pediatric Brain Tumor Patients
Dr. Stephanie Perkins – Washington University in St. Louis, St Louis, MO
Discovery of novel MDM2-targeted therapy for pediatric AML
Discovery of novel MDM2-targeted therapy for pediatric AML
Dr. Muxiang Zhou – Emory University, Atlanta, GA
Deciphering the Immune Microenvironment in Alveolar Rhabdomyosarcoma
Deciphering the Immune Microenvironment in Alveolar Rhabdomyosarcoma
Dr. Brian Ladle - Johns Hopkins University School of Medicine, Baltimore, MD
Delineating molecular mechanisms of metastatic dissemination for medulloblastoma therapy
Delineating molecular mechanisms of metastatic dissemination for medulloblastoma therapy
Dr. Baoli Hu – University of Pittsburgh, Pittsburgh, PA
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Dr. Zhaohui Gu – Beckman Research Institute of the City of Hope, Duarte, CA
Dual-label optical genome mapping for the identification of novel co-occurring genetic and epigenetic alterations in diffuse midline gliomas
Dual-label optical genome mapping for the identification of novel co-occurring genetic and epigenetic alterations in diffuse midline gliomas
Dr. Miriam Bornhorst – Children's National Health System Department of Neurology, Washington D.C.
Preclinical evaluation of BRD inhibitors to treat Posterior Fossa A ependymoma
Preclinical evaluation of BRD inhibitors to treat Posterior Fossa A ependymoma
Dr. Oren Becher – Icahn School of Medicine at Mount Sinai, New York, NY
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Beckman Research Institute of the City of Hope, Duarte, CA
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Baylor College of Medicine, Houston, TX
Optimizing Pediatric Cancer Immunotherapy with Nano-Targeted Off-the-Shelf Natural Killer T Cells
Optimizing Pediatric Cancer Immunotherapy with Nano-Targeted Off-the-Shelf Natural Killer T Cells
University of Miami, Miami, FL
Characterizing the ENL YEATS epigenetic reading domain as a therapeutic target in pediatric MLL-ENL leukemias
Characterizing the ENL YEATS epigenetic reading domain as a therapeutic target in pediatric MLL-ENL leukemias
The Regents of the University of Michigan, Ann Arbor, MI
Targeting ATR/SPOP Signaling to Overcome Chemotherapy Resistance in Ewing Sarcoma
Targeting ATR/SPOP Signaling to Overcome Chemotherapy Resistance in Ewing Sarcoma
The University of North Carolina at Chapel Hill, Chapel Hill, NC
Investigating the role of PSAT1 in tumor-associated macrophages for sarcoma immunotherapy
Investigating the role of PSAT1 in tumor-associated macrophages for sarcoma immunotherapy
Case Western Reserve University - School of Medicine, Cleveland, OH